NASDAQ: PYPD - PolyPid Ltd.

Yield per half year: -21.31%
Dividend yield: 0.00%
Sector: Healthcare

Share chart PolyPid Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About PolyPid Ltd.

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-06-26
ISIN IL0011326795
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.polypid.com
Цена ао 2.75
Change price per day: 0% (2.699)
Change price per week: +7.44% (2.512)
Change price per month: -12.08% (3.07)
Change price per 3 month: -16.7% (3.24)
Change price per half year: -21.31% (3.43)
Change price per year: -39.21% (4.44)
Change price per 3 year: -45.69% (4.97)
Change price per year to date: -16.18% (3.22)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -2.42 0
P/E 0 0
EV/EBITDA -0.5341 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -155.25 0
ROE, % 1138.6 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.519 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -30.61 0
Yield EPS, % -4857.39 0
Total: 0
More

Institutions Volume Share, %
Yelin Lapidot Holdings Management Ltd. 11153 0.23
Steward Partners Investment Advisory, LLC 7346 0.15
Morgan Stanley 878 0.02
Osaic Holdings Inc 800 0.02
UBS Group AG 764 0.02



Head Job title Payment Year of birth
Ms. Dikla Czaczkes Akselbrad CEO & Director 347.88k 1973 (52 years)
Ms. Dalit Hazan Deputy CEO and Executive VP of R&D, Clinical & Regulatory Affairs 272.38k 1971 (54 years)
Mr. Ori Warshavsky Chief Operating Officer - US 340.89k 1978 (47 years)
Mr. Jonny Missulawin Chief Financial Officer 186.96k 1987 (38 years)
Ms. Maria Rubin Vice President of Operations N/A
Mr. Tal Vilnai General Counsel & Corporate Secretary N/A
Ms. Rivi Lev-ari Vice President of Human Resource N/A
Dr. Jean-Marc Hagai Pharm.D. Chief Commercial Officer N/A

Address: Israel, Petah Tikva, 18 Hasivim Street - open in Google maps, open in Yandex maps
Website: https://www.polypid.com